Pfizer: U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-In-Class Treatment for Patients With Chronic Pain Due to Moderate-to-Severe Osteoarthritis
March 03, 2020
March 03, 2020
NEW YORK, March 3 -- Pfizer, a pharmaceutical company, issued the following news release:
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC), which is being evaluated for patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesi . . .
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC), which is being evaluated for patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesi . . .